WINDWARD BIO GROUP AG 424B4final IPO prospectus
PositivePre-revenue
Develops long-acting antibodies for asthma and other inflammatory diseases; $175M raise funds trials led by WIN378’s potential twice-yearly dosing
Filed 2026-11-13 18:33 ET · Listing on Nasdaq
How this filing reads
Each score is our read of the filing's tone, not a rating. The bar runs from −1 (bad) to +1 (good). The tick marks the typical filing on Goblin, and the shaded band is where the middle half of filings score.How we read filings
- HealthPost-IPO cash and securities of $411M, no borrowings, and projected runway into H1 2029 support obligations.
- Momentumnot enough history
- OutlookWIN378 Phase 3 began in 9/2026; asthma readouts are expected in H1 2029.
The final prospectus, filed when the IPO priced.
Executive Summary
Windward Bio develops antibody medicines for patients with asthma, chronic obstructive pulmonary disease and atopic dermatitis; it has no approved products or revenue. Its strategy is to make established inflammatory targets treatable with much less frequent injections, led by WIN378’s potential twice-yearly dosing. Clinical expansion is accelerating spending rather than sales: H1 2026 net loss reached $(42.6)M, and management expects substantial continuing losses. The $175M all-primary IPO implies a minimum fully diluted valuation of $1.09B, with IPO buyers owning 16.1%; buyers are funding the clinical proof needed to turn promising early findings into approved, differentiated medicines.
Business Model and Growth Drivers
WWB’s prospective business is medicine sales, but today it funds development with equity. Its licensed territories exclude Greater China and, for WIN378, certain other Asian markets. Management estimates a $60B peak biologics opportunity across its initial diseases; commercial success requires convincing physicians and payers that longer dosing intervals improve treatment without sacrificing efficacy or safety.
WIN378 targets thymic stromal lymphopoietin, an inflammatory signaling protein. In POLARIS-1’s 147-patient Phase 2 asthma study, interim findings after one dose included sustained lung-function and inflammation improvements through week 24, with placebo-adjusted lung-function improvement of up to 267 milliliters. No treatment-related serious adverse events were reported at the cutoff. These findings support testing twice-yearly dosing, but do not establish fewer asthma exacerbations or pivotal-trial success. Phase 3 began in 9/2026, with both asthma Phase 3 readouts expected in H1 2029.
WIN027 targets the same protein plus interleukin-13. It remains in healthy-volunteer testing; global Phase 2 studies in obstructive pulmonary disease and atopic dermatitis are planned to recruit in H1 2027. Partner Qyuns is conducting separate Chinese studies, creating additional data opportunities but also partner and regulatory dependencies.
WWB owns no manufacturing facilities. WIN378’s transfer from Chinese production to U.S. contractors is expected by year-end 2026; WIN027’s planned U.S. transfer has not begun. Supply readiness must keep pace with expanding trials.
The Offering
- At $17.00, 10.3M primary shares raise $175M gross. Implied capitalization is $987M on 58.0M outstanding shares; IPO buyers receive 17.7%. The minimum fully diluted count is 63.9M, implying $1.09B and 16.1%, including outstanding options, restricted stock units, planned IPO options and Sanofi warrants. It excludes unused plan reserves and unspecified additional treasury issuance. Revenue and earnings multiples are not meaningful.
- Sanofi concurrently invests $50.0M for 1.53M shares and zero-exercise-price warrants covering 1.41M shares. Its placement depends on the IPO closing, not vice versa. Estimated combined net proceeds are $204M, all received by WWB.
- Proceeds plus existing funds are allocated principally to WIN378 ($218M–$228M), WIN027 ($80M–$85M) and earlier bispecific programs ($5M–$10M), with the remainder for corporate needs. Management projects funding into H1 2029 but expects further financing.
- Each $17.00 share is backed by $6.74 of net tangible assets after the IPO, a $10.26 gap. Existing holders paid an average $6.71 per share. These figures use the specifically labeled dilution table.
- Pricing was 11/12/2026; delivery is expected on or about 11/16/2026. Nasdaq ticker: WWB. Underwriters are Jefferies, TD Securities, Piper Sandler and UBS, with a 30-day option for 1.54M additional shares.
- Generally, directors, executives and substantially all existing holders face 180-day lock-ups ending 5/11/2027, subject to exceptions and early release. Initially restricted shares represent 82% of outstanding shares, creating a sizeable potential resale overhang.
Key Financial Highlights
$M; losses and outflows in parentheses. Financial statements follow International Financial Reporting Standards.
| Metric | 2024 inception period¹ | FY2025 | H1 2025 | H1 2026 | After IPO² |
|---|---|---|---|---|---|
| R&D expense | 0.084 | 32.6 | 13.3 | 30.1 | — |
| Operating loss | (1.19) | (51.8) | (23.3) | (44.7) | — |
| Net loss | (1.19) | (48.3) | (22.8) | (42.6) | — |
| Operating cash flow | (0.074) | (33.3) | (9.71) | (25.9) | — |
| FCF³ | — | (33.8) | (9.82) | (26.0) | — |
| Cash and equivalents | 0.147 | 19.8 | 12.9 | 18.9 | 223 |
| Total liabilities | 1.26 | 27.0 | — | 25.0 | — |
| Equity | (1.08) | 192 | — | 266 | 471 |
| Tangible equity | (1.08) | 117 | — | 186 | 391 |
¹ 7/5/2024–12/31/2024; operations began in 1/2025, limiting comparability.
² June 30 balance sheet adjusted for preferred conversion, warrant settlement, IPO and Sanofi placement, without the underwriters’ option.
³ Operating cash flow minus property and equipment purchases.
- Spending: H1 R&D increased 126%, principally as clinical/manufacturing services and materials rose to $22.2M from $9.52M. Trial expansion explains the accelerating losses.
- Loss versus cash use: H1 stock-based compensation of $8.81M was an expense without cash payment; increased unpaid supplier bills also reduced immediate cash use. Investment fair-value gains of $2.08M narrowed net loss without improving operating performance.
- Funding bridge: Cash plus marketable securities rises from $207M before the IPO to $411M after it. Net proceeds add $204M; warrant-liability reclassification adds $1.57M to equity. There are no outstanding borrowings. The small 2024 equity deficit reflected inception-period losses, not preferred-stock exclusion.
- License economics: Contingent obligations include WIN378 development milestones up to $320M and sales milestones up to $600M per product; WIN027 adds up to $100M and $570M, respectively, plus royalties. These are not current debts, but can consume future financing or commercial returns.
Governance and Control
- One common class remains after conversion, generally with one vote per share, subject to a 14% voting cap and board exceptions. Directors and executives collectively hold 30.3%; Novo Holdings and OrbiMed hold 10.6% and 10.2%, respectively.
- CEO Luca Santarelli also chairs the board. WWB acquired executive-founded Windward Bio 27 for 2.27M shares, creating related-party interests alongside development incentives.
- Outstanding options, restricted stock units and planned IPO options total 4.46M shares, or 7.0% of minimum fully diluted shares. Earlier options’ implied intrinsic value is $26.4M at the IPO price; future plan reserves and annual increases permit further dilution.
- Swiss foreign-private-issuer and emerging-growth-company exemptions allow less frequent disclosure and reduced governance requirements, limiting investor oversight.
Risk Assessment
- Clinical concentration: Both lead assets remain investigational; early lung-function, biomarker and safety findings may not translate into approval.
- Financing timing: Projected runway reaches the same half-year as pivotal asthma readouts, leaving limited room for delays before another capital raise.
- Partner and supply dependence: Chinese licensors, partner-generated data and unfinished manufacturing transfers expose development to execution and geopolitical disruption.
- Commercial differentiation: Longer dosing alone may not overcome established therapies, competing long-acting candidates or payer restrictions.
- Dilution and influence: Equity awards, issuance authority and the lock-up expiry can dilute ownership or pressure trading, while voting restrictions constrain shareholder influence.
What to Watch
- WIN378: H1 2027 Phase 2 primary results and H2 2027 obstructive-pulmonary-disease results should test whether early signals persist; weaker efficacy or safety findings would undermine the lead asset.
- WIN027: Full Phase 1 data and planned H1 2027 Phase 2 recruitment should establish whether long-duration exposure supports patient testing; delays or tolerability problems would weaken pipeline diversification.
- Funding: Management projects resources into H1 2029. Later spending and financing disclosures will show whether WWB reaches pivotal readouts with flexibility or must raise capital beforehand.
Longer version: the summary of each of the prospectus's 30 sections, written by an AI model from the same filing.
Get emails when companies you follow file: email digest settings.
The summary and scores is written by an AI model reading the filing.
Model 006 · prompt v222 · 2026-11-16 15:41:45Z